|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Tirofiban#Overdosage]] |
| {{Tirofiban}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Overdosage==
| |
| In clinical trials, inadvertent overdosage with AGGRASTAT occurred in doses up to 2 times the recommended dose for initial infusion doses. Inadvertent overdosage occurred in doses up to 9.8 times the 0.15 mcg/kg/min maintenance infusion rate.
| |
| | |
| The most frequently reported manifestation of overdosage was bleeding, primarily minor mucocutaneous bleeding events and minor bleeding at the sites of cardiac [[catheterization]] [see WARNINGS AND PRECAUTIONS (5.1)].
| |
| | |
| Overdosage of AGGRASTAT should be treated by assessment of the patient’s clinical condition and cessation or adjustment of the drug infusion as appropriate. | |
| | |
| AGGRASTAT can be removed by [[hemodialysis]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = AGGRASTAT (TIROFIBAN) INJECTION, SOLUTION [MEDICURE INTERNATIONAL INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fe0ced75-ccbf-4d2e-bd0d-b57e60ab913f | publisher = | date = | accessdate = 6 February 2014 }}</ref>
| |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Antiplatelet drugs]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}
| |